Running out of creative ways to hide your **discoid lupus?**

Learn about a research study for people with skin lupus



About the HZNP-DAX-202 DLE Study

The HZNP-DAX-202 DLE Study is evaluating a study drug to see if it may reduce symptoms of a type of skin lupus known as discoid lupus erythematosus, or DLE. Discoid lupus commonly appears as disc-shaped sores or rashes on your face, neck, ears, scalp, hands, and feet. If you still have moderate to severe discoid lupus symptoms even with medication, or you could not tolerate the medication's side effects, this research study may be an option. Participants must have lupus that affects **only their skin, not lupus that affects other organs of your body**, also known as systemic lupus erythematosus (SLE).

About the study drug

The study drug works differently from other medications for DLE to reduce inflammation. It is administered by subcutaneous (under the skin) injection once every 4 weeks at the study site. In the first half of the research study, some participants will be given a placebo (which looks like the study drug but contains no active drug). In the second half of the research study, everyone will get the study drug.

You may be eligible to participate if you:*

- Are 18 to 75 years old
- Have been diagnosed with discoid lupus for at least 6 months
- Currently experience moderate to severe skin symptoms related to discoid lupus
- Have tried medication for discoid lupus but it hasn't worked well enough, or you could not tolerate the side effects
- Have discoid lupus that affects only your skin, not other organs of your body (SLE)

*The study team can discuss additional eligibility criteria with you.

Why participate?

If you qualify and decide to take part, you will receive:

- All study-related care and the study drug at no charge
- Regular monitoring of your DLE and overall health by physicians who specialize in DLE and other types of lupus
- The opportunity to contribute to advancing scientific knowledge about DL

Your safety while participating in the HZNP-DAX-202 DLE Study is our highest priority. If you have any questions or concerns at any point throughout the research study, a study team member is available. The study team can also tell you about their COVID-19 safety protocols.

Your participation in any research study is voluntary, and you are always free to withdraw at any time for any reason. Your privacy will be maintained throughout the research study.

For more information or to see if you qualify: HorizonDLEStudy.com

